PGIM Investments Head of ETFs on PGIM AAA CLO ETF (PAAA)
PGIM Investments Head of ETFs Matt Collins discusses the PGIM AAA CLO ETF (ticker: PAAA) and says the path of interest rates "take far longer than most people expect," and CLO drawdowns are "limited." He speaks with Scarlet Fu and Katie Greifeld on "ETF IQ."
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
15 hours ago
- Yahoo
QQQM Tops $50B as Investors Seek Low-Cost QQQ Alternative
The Invesco NASDAQ 100 ETF (QQQM) hit a major milestone this week, crossing $50 billion in assets under management less than four years after its launch. Often referred to as the 'cheaper QQQ,' QQQM is functionally identical to the Invesco QQQ Trust (QQQ), tracking the same Nasdaq-100 index. But there's one key difference: fees. QQQM charges an expense ratio of 0.15%, undercutting QQQ's 0.2% five-basis-point difference might seem small, but for long-term investors—especially those focused on cost efficiency—it's made a big impact. Since QQQM's inception in October 2020, the fund has delivered a total return of 86.5%, just ahead of QQQ's 85.9%. Investor demand has followed. QQQM has pulled in $8.8 billion of net inflows so far in 2025, the sixth-most of any ETF this year. Over the past 12 months, it has attracted $17.1 billion. QQQ, for its part, continues to draw significant interest as well, with $8 billion in year-to-date inflows and $22.3 billion over the past year. It remains one of the largest ETFs in the world, with nearly $340 billion in assets, making it the fifth-largest ETF listed in the U.S. While QQQM has become the go-to version for buy-and-hold investors due to its lower fee, QQQ still dominates in one area: liquidity. QQQ boasts one of the most active and deepest options markets of any ETF, making it the preferred choice for traders and institutions needing flexibility or hedging tools. Both ETFs are riding the continued popularity of the Nasdaq-100 index, a tech-heavy benchmark that holds the 100 largest nonfinancial stocks listed on the Nasdaq exchange. Technology stocks make up about 57% of the index's weight, but it also includes major names from other sectors like consumer discretionary, healthcare and industrials. With demand for mega-cap tech showing no signs of slowing, both QQQ and QQQM remain essential tools for investors seeking concentrated exposure to the sector's biggest | © Copyright 2025 All rights reserved
Bloomberg
16 hours ago
- Bloomberg
Stocks Finish Higher on Thin Volume
Comprehensive cross-platform coverage of the U.S. market close on Bloomberg Television, Bloomberg Radio, and YouTube with Romaine Bostick, Alix Steel, Scarlet Fu, Carol Massar and Tim Stenovec. (Source: Bloomberg)
Yahoo
a day ago
- Yahoo
Should You Invest in the SPDR S&P Biotech ETF (XBI)?
Designed to provide broad exposure to the Healthcare - Biotech segment of the equity market, the SPDR S&P Biotech ETF (XBI) is a passively managed exchange traded fund launched on 01/31/2006. Retail and institutional investors increasingly turn to passively managed ETFs because they offer low costs, transparency, flexibility, and tax efficiency; these kind of funds are also excellent vehicles for long term investors. Additionally, sector ETFs offer convenient ways to gain low risk and diversified exposure to a broad group of companies in particular sectors. Healthcare - Biotech is one of the 16 broad Zacks sectors within the Zacks Industry classification. It is currently ranked 6, placing it in top 38%. The fund is sponsored by State Street Global Advisors. It has amassed assets over $4.92 billion, making it one of the largest ETFs attempting to match the performance of the Healthcare - Biotech segment of the equity market. XBI seeks to match the performance of the S&P Biotechnology Select Industry Index before fees and expenses. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the U.S. common stocks listed on the NYSE, AMEX, NASDAQ National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index. Cost is an important factor in selecting the right ETF, and cheaper funds can significantly outperform their more expensive counterparts if all other fundamentals are the same. Annual operating expenses for this ETF are 0.35%, making it one of the least expensive products in the space. It has a 12-month trailing dividend yield of 0.16%. Even though ETFs offer diversified exposure which minimizes single stock risk, it is still important to look into a fund's holdings before investing. Luckily, most ETFs are very transparent products that disclose their holdings on a daily basis. This ETF has heaviest allocation in the Healthcare sector--about 100% of the portfolio. Looking at individual holdings, Exact Sciences Corp (EXAS) accounts for about 3.12% of total assets, followed by Alnylam Pharmaceuticals Inc (ALNY) and Neurocrine Biosciences Inc (NBIX). The top 10 holdings account for about 27.11% of total assets under management. So far this year, XBI has lost about -6.31%, and is down about -8.60% in the last one year (as of 06/12/2025). During this past 52-week period, the fund has traded between $69.80 and $104.18. The ETF has a beta of 0.86 and standard deviation of 30.70% for the trailing three-year period, making it a high risk choice in the space. With about 129 holdings, it effectively diversifies company-specific risk. SPDR S&P Biotech ETF carries a Zacks ETF Rank of 3 (Hold), which is based on expected asset class return, expense ratio, and momentum, among other factors. Thus, XBI is a reasonable option for those seeking exposure to the Health Care ETFs area of the market. Investors might also want to consider some other ETF options in the space. First Trust NYSE Arca Biotechnology ETF (FBT) tracks NYSE Arca Biotechnology Index and the iShares Biotechnology ETF (IBB) tracks Nasdaq Biotechnology Index. First Trust NYSE Arca Biotechnology ETF has $1.04 billion in assets, iShares Biotechnology ETF has $5.32 billion. FBT has an expense ratio of 0.56% and IBB charges 0.45%. To learn more about this product and other ETFs, screen for products that match your investment objectives and read articles on latest developments in the ETF investing universe, please visit Zacks ETF Center. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report SPDR S&P Biotech ETF (XBI): ETF Research Reports Alnylam Pharmaceuticals, Inc. (ALNY) : Free Stock Analysis Report iShares Biotechnology ETF (IBB): ETF Research Reports Neurocrine Biosciences, Inc. (NBIX) : Free Stock Analysis Report Exact Sciences Corporation (EXAS) : Free Stock Analysis Report First Trust NYSE Arca Biotechnology ETF (FBT): ETF Research Reports This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
